Abstract
By assessing a patient's genetic makeup at a low cost, next-generation sequencing (NGS) technologies have begun to change the area of hematological malignancies. High-throughput, massively parallel DNA sequencing technologies are rapidly revealing new information in hematology, cancer, clinical genetics, and a variety of other diseases. It provides researchers with a new viewpoint on the onset of sickness, risk assessment, and therapeutic action. In hematology these technologies are used to diagnose hematological malignancies, inherited coagulation bleeding disorders, minimal residual diseases, hereditary hemolytic anemia, and blood typing. The use of next-generation sequencing in regular diagnostic procedures raises a number of challenges, including result interpretation, laboratory workflow, data storage, and ethical concerns.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Hematology & Transfusion International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
